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h i g h l i g h t s
• Alpha1-chimaerin mRNA was localized to neurons in postmortem human brain.
• Reduced mRNA levels of ˛1-chiamerin in the temporal cortex and hippocampus of AD.
• Expression of ˛2-chimaerin mRNA was not reduced in the temporal cortex of AD.
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a b s t r a c t
Alpha1-chimaerin is a GTPase-activating protein (GAP) for Rac1, a member of the Rho small GTPase fam-
ily, whose action leads to the inactivation of Rac1. Rac1 activity is upregulated in Alzheimer’s disease,
but little is known about the role of ˛1-chimaerin. In this study, we investigated the expression and
localization of ˛1-chimaerinmRNA in postmortem human brains from patients with Alzheimer’s disease
and control subjects. In situ hybridization studies demonstrated that ˛1-chimaerin was expressed by
neurons in the neo-cortex of the temporal lobe and the hippocampus of both controls and Alzheimer’s
disease cases, with the signal intensity dramatically decreased in patientswith Alzheimer’s disease. Real-
time PCR analysis conﬁrmed a signiﬁcant reduction of ˛1-chimaerin mRNA expression in the temporal
cortex of Alzheimer’s disease cases. In contrast, ˛2-chimaerin mRNA levels showed no signiﬁcant dif-
ference between the groups. The present study showed reduced ˛1-chimaerin expression in the brain
of Alzheimer’s disease cases, suggesting a role in the upregulation of Rac1 activity during the disease
process.
© 2015 Elsevier Ireland Ltd. All rights reserved.
1. Introduction
Alpha1-chimaerin is a GTPase-activating protein (GAP) for Ras-
related C3 botulinum toxin substrate 1 (Rac1), a member of the
Rho small GTPase family [1,2]. Alpha1-chimaerin is selectively
expressed in the brain, where its Rac1 GAP activity mediates Rac1
inactivation. Rac1 regulates actin polymerization, actin reorgani-
zation, cell migration, and cell cycle progression [3]. In neurons,
Rac1 mediates dendritic spine formation and other morphological
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changes [4,5]. By inactivating Rac1, ˛1-chimaerin plays a signif-
icant role in the regulation of dendritic growth during neuronal
development in the brain [6].
Alpha-chimaerin consists of two splice variants (˛1 and ˛2).
The ˛1 variant lacks the N-terminal SH2 domains and is more
abundant in the adult brain than during development, whereas
the ˛2 variant is mainly expressed in the developing brain and
testes [7,8]. Increased ˛1-chimaerin promotes the pruning of
dendritic branches and arbors, and ˛1-chimaerin overexpression
causes loss of spines in the mouse brain [6]. In cultured hip-
pocampus, ˛1-chimaerin inhibits the formation of new spines and
removesexisting spines [9]. Conversely, thedown-regulationof˛1-
chimaerin increases protrusive activity from the dendrite, resulting
in an increased abundance of neurons with morphologically atypi-
cal spines [6]. Therefore, ˛1-chimaerin is thought to be a regulator
http://dx.doi.org/10.1016/j.neulet.2015.02.013
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of dendritic spine growth, branching, and morphology that exerts
its function by increasing synaptic activity via muscarinic acetyl-
choline receptors [6] and N-methyl-d-aspartate (NMDA) receptors
[9], leading to pruning of dendritic arbors for precisely selected
synaptic formation [6].
Alzheimer’s disease (AD) is the most common cause of demen-
tia associated with the accumulation of ß-amyloid (Aß) plaques
[10–13], formation of neuroﬁbrillary tangles [14], and neuronal
death. In addition, synaptic loss is implicated as a major struc-
tural cause of cognitive dysfunction in AD [15], probably involving
loss or alterations of dendritic spine formation [16]. Aß oligomers
disrupt synaptic plasticity in vivo [17] and cause synaptic dysfunc-
tion in an animal model of AD [18]. A previous study has reported
that Rac1 activity is upregulated in the hippocampus of ADpatients
[19]. However, little information is available about the expression
of ˛1-chimaerin in the brain of AD patients. In this study, we there-
fore investigated the expression and localization of ˛1-chimaerin
in postmortem brains of patients with AD and of age-matched,
neuropathologically normal controls at the mRNA level.
2. Materials and methods
2.1. Subjects
All subjectswere from the Banner SunHealth Research Institute
Brain and Body Donation Program [20]. The tissue was processed
following previously described methods [21,22]. The clinicopatho-
logical data are summarized in Table 1.
For quantitative real-time PCR, total RNA was extracted from
the temporal cortex of seven sporadic AD cases (mean age± SD,
86.3±4.8 years) and eight control subjects without neurological
disease (mean age± SD, 81.3±4.8 years). The mean postmortem
delays for the AD cases and control subjects were 2.67h and 2.51h,
respectively.
For in situ hybridization histochemistry, we examined the hip-
pocampus and the temporal cortex of three sporadic AD cases
(meanage± SD, 71.7±10.1 years) and three control subjects (mean
age± SD, 83.0±4.4 years).
2.2. In situ hybridization
The hybridization probe was designed to detect the N-terminal
region speciﬁc to ˛1-chimaerin (bases 1–175 from the initiation
codon; accession number S75654). The N-terminal regions of ˛1-
chimaerin were subcloned into the pGEM-T easy vector (Promega,
Madison, WI, USA), and the digoxigenin-UTP-labeled sense and
antisense riboprobes were synthesized, according to the manufac-
turer’s protocol.
Frozen, ﬁxed 40m sections of the postmortem brain were
mounted on RNase-free silane-coated glass slides (Dako Japan
Co., Ltd., Tokyo, Japan) and air-dried before immersion in diethyl
pyrocarbonate-treated phosphate-buffered saline (0.1M, pH 7.4)
for 10min. The sections were then treated for 10min at room tem-
perature with proteinase K (5g/ml) in 10mM tris-HCl buffer (pH
8.0) containing 150mM NaCl at 37 ◦C, and then post-ﬁxed with
4% paraformaldehyde in 0.1M phosphate buffer (pH 7.4) at room
temperature for 10min. The sections were pre-hybridized for 2h
at 37 ◦C in a hybridization buffer [50% formamide, 5×denhardt’s
solution, 3× saline/sodium citrate (SSC), 0.5mg/ml yeast tRNA,
and 0.5mg/ml heat-denatured salmon sperm DNA]. The probes
were diluted in the hybridization buffer to a ﬁnal concentra-
tion of 2g/ml, and hybridization was performed for 16h at
60 ◦C. After hybridization, the sections were washed for 2h
in 0.2× SSC buffer at 60 ◦C, followed by rinsing in 0.1M tris-
HCl (pH 7.5) containing 150mM NaCl (NT buffer) for 5min at
room temperature. The sections were blocked in 1% skim milk
in NT buffer for 60min, and incubated overnight at 4 ◦C with
Table 1
Clinicopathological data of study subjects.
Case # Pathological
diagnosis
Age (years) Gender Postmortem
delay (h)
Clinical diagnosis
and complications
CERAD neuritic
plaque score
Braak
neuroﬁbrillary
tangle stage
Analysis
1 Control 81 F 3.0 Myocardial infarction, congestive
heart failure, renal failure
A II qPCR
2 Control 78 M 2.7 Coronary artery disease, chronic,
obstructive pulmonary disease,
congestive heart failure, diabetes
mellitus, hip bone fracture, cardiac
pacemaker
0 II qPCR
3 Control 82 F 2.0 Lung cancer, myocardiac infarction A II qPCR
4 Control 73 F 1.5 Ovarian cancer 0 I qPCR
5 Control 85 F 2.5 Cardiac and respiratory failure,
atrial ﬁbrillation, cerebrovascular,
accident (right hemiplegia)
0 III qPCR
6 Control 78 M 1.7 Lung cancer, heart failure 0 I qPCR, ISH
7 Control 85 M 3.2 Congestive heart failure 0 II qPCR, ISH
8 Control 88 F 3.0 Chronic renal failure 0 II qPCR
9 Control 86 M 2.5 Renal failure, attrial fabrillation,
coronary artery disease, congestive
heart failure
0 II ISH
10 AD 89 F 3.0 AD, osteoarthritis, anxiety,
depression, aspiration pneumonia
C V qPCR
11 AD 79 M 2.0 AD C V qPCR
12 AD 89 F 3.0 AD bronchopneumonia C V qPCR
13 AD 80 F 2.2 AD, parkinsonism C VI qPCR
14 AD 91 F 3.0 AD C V qPCR
15 AD 87 M 3.0 AD parkinsonism C V qPCR
16 AD 89 F 2.5 AD C VI qPCR
17 AD 61 F 2.5 AD, uterus cancer, bronchitis C VI ISH
18 AD 73 F 2.0 AD, atrial ﬁbrillation,
cerebrovascular accident
C V ISH
19 AD 81 M 3.0 AD, cardiac and respiratory failure, C V ISH
AD: Alzheimer’s disease, qPCR: quantitative polymerase chain reaction, ISH: in situ hybridization histochemistry.
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Fig. 1. In situ hybridization of ˛1-chimaerin mRNA in the temporal cortex of control subjects (A, C and D) and AD cases (B and E) using an antisense probe (A, B, D and E) or
a sense probe (C). (A) and (B): positive signals were detected in the cortex of both control subjects and AD cases. (C): no signals were detected using the sense probe with
the exception of nuclear staining in areas near the cortical surface of layer 1. (D) and (E): high magniﬁcation of the boxed area in layer 3 of a control (A) and an AD case (B).
Positive cells appear to be neurons. Scale bar =200m in A–C, and 50m in D and E.
alkaline phosphatase-labeled anti-digoxigenin antibody (1:200;
Roche Diagnostics, Basel, Switzerland). The signal was detected
using the substrates nitroblue tetrazolium chloride and 5-bromo-
4-chloro-3-indolyl phosphate p-toluidine salt.
2.3. Quantitative real-time PCR
Five micrograms of each total RNA sample was reverse-
transcribed for ﬁrst-strand cDNA synthesis using 80 units of
superscript II (Gibco BRL, Gaithersburg, MD, USA) and 500pmol of
oligo dT12–18 (Amersham Biosciences Corp., Piscataway, NJ, USA).
The reaction mixture consisted of 1× LC-FastStart mixture,
4mM MgCl2, 0.5M of primer, and 200ng of cDNA. We designed
a set of primers to amplify ˛1-chimaerin mRNA, but not ˛2-
chimaerin, and conﬁrmed on agarose gels that the PCR product
was a single band. Real-time PCR primers for the reactions
were as follows: ˛1-chimaerin, 5′-AAAATGCCATCCAAAGAGTCT-
3′ (sense, 2170–2190 in GenBank accession number
S75654) and 5′-GAAATTGTGAATCTTTTCATATTT-3′
(antisense, 2398–2421 in S75654); ˛2-chimaerin, 5′-
GGCTCTACTACGATGGCAAGC-3′ (sense, 297–317 in Z22641)
and 5′-CTGTAGAATCTCTCTCATCATGT-3′ (antisense, 511–533 in
Z22641); ß-actin, 5′-TGGTGGGCATGGGTCAGAAGGATTC-3′ (sense,
172–196 in X00351) and 5′-CATGGCTGGGGTGTTGAAGGTCTCA-3′
(antisense, 413–437 in X00351); and MAP2, 5′-
CTGTAGCAGTCCTGAAAGGTGA-3′ (sense, 454–475 in BC027583)
and 5′-TGCTAGGGCAGGCTGAGCTGTATC-3′ (antisense, 718–741
in BC027583). Cycling conditions comprised an initial 10min of
incubation at 95 ◦C followed by 1–40 cycles of denaturation for
15 s at 95 ◦C, annealing for 8 s at 54 ◦C for ˛1-chimaerin, for 5 s at
56 ◦C for ˛2-chimaerin, or for 5 s at 58 ◦C for ß-actin and MAP2,
and extension for 15 s at 72 ◦C. Standard curves were obtained
from plasmids containing ˛1-chimaerin or ˛2-chimaerin cDNA.
According to the ﬁt points method of lightcycler, we calculated
mRNA content using the standard curves. The expression levels
of ˛1- and ˛2-chimaerin mRNAs in neurons were normalized to
ß-actin and MAP2, respectively. Statistical analysis was performed
using student’s unpaired t-test.
3. Results
3.1. ˛1-chimaerin mRNA was downregulated in the temporal
cortex of AD patients, as demonstrated by in situ hybridization
In situ hybridization detected ˛1-chimaerin mRNA in the tem-
poral cortex of both control subjects (Fig. 1A) andAD cases (Fig. 1B).
No signal was detected using the sense probe with the exception of
nuclear staining in areas near the cortical surface of layer 1 (Fig. 1C).
At high magniﬁcation, positive signals were localized to neurons
(Fig. 1D and E, supplementary Fig. S1). Although there was no dif-
ference in the localization of ˛1-chimaerin mRNA between control
subjects and AD cases, the signal intensity dramatically decreased
in the cerebral cortex of AD patients (Fig. 1B and E), compared with
those of control subjects (Fig. 1A and D).
In the hippocampus of control cases (Fig. 2), ˛1-chimaerin
mRNA was strongly expressed in the pyramidal neurons of the
cornu ammonis (CA) (Fig. 2A and B) and in the granule cells of
the dentate gyrus (DG) (Fig. 2C); however, this signal intensity was
dramatically decreased in pyramidal neurons (Fig. 2D and E) and
granule cells (Fig. 2F) of AD cases.
3.2. Reduced ˛1-chimaerin mRNA levels in the temporal cortex of
AD patients were conﬁrmed by real-time PCR analysis
Real-time PCR was used to compare the expression levels
of ˛1-chimaerin mRNA between AD cases and control subjects
(Fig. 3). Statistical data are presented in Table 2. We used 200ng
of cDNA from the temporal cortex for the real-time PCR, and calcu-
lated the contents according to a standard curve generated using
the ˛1-chimaerin plasmid. The expression levels of ˛1-chimaerin
mRNA in control subjects and AD cases were 1185.49±163.97 fg
(mean± SEM, n=8) and 263.75±134.12 fg (mean± SEM, n=7),
respectively.Whennormalized to ß-actin andMAP2, ˛1-chimaerin
mRNA levels in the AD cases were reduced to 37.3% and 31.3%,
respectively, compared to control levels (P<0.01, Table 2 and
Fig. 3A).
We also examined the expression of ˛2-chimaerin mRNA using
real-time PCR. The relative expression levels of ˛2-chimaerin
mRNA in the control subjects and AD cases were 18.53±1.22
(mean± SEM, n=8) and 8.95±2.22 (mean± SEM, n=7), respec-
tively, with no signiﬁcant difference detected between the
Table 2
Alpha-chimaerin mRNA expression levels in the temporal cortex of Alzheimer’s
disease cases and control subjects.
Control (n=8) Alzeimer’s disease P-value
˛1-chimaerin/ß-actin 0.50 ± 0.08 0.18 ± 0.04 0.0053**
˛1-chimaerin /MAP2 553.09 ± 70.00 173.1 ± 94.7 0.0060**
˛2-chimaerin/ß-actin 0.0051 ± 0.0004 0.0058 ± 0.0008 0.407
˛2-chimaerin/MAP2 9.40 ± 1.56 6.13 ± 1.61 0.169
Values are presented as mean± SEM.
** P<0.01.
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Fig. 2. In situ hybridization of ˛1-chimaerin mRNA in the hippocampus of a control subject (A–C) and AD case (D–F). (A) and (D): at low magniﬁcation, positive signals were
mainly visible in the pyramidal layers of the cornu ammonis (CA) and granular cell layer of the dentate gyrus (DG) in both control subjects and AD cases. (B) and (E): high
magniﬁcation of the pyramidal layer of the CA2 region. (C) and (F): high magniﬁcation of the granular cell layer of the dentate gyrus. Signal intensity is reduced in the AD
case (D–F) relative to that in controls (A–C). Scale bar =200m in (A) and (D); 100m in (B, C, E and F).
Fig. 3. mRNA expression levels of ˛1-chimaerin (A) and ˛2-chimaerin (B) in the temporal cortex of patients with AD (n=7) and control cases (n=8) using real-time PCR.
The mRNA expression levels of ˛1-chimaerin and ˛2-chimaerin are normalized to the ß-actin and MAP2 mRNA levels. The mRNA expression level of ˛1-chimaerin, but not
˛2-chimaerin, is signiﬁcantly reduced in the temporal cortex of AD cases compared to controls. Results are presented as mean± SEM. Statistical analysis was performed
using student’s t-test: **P <0.01 vs. control cases.
groups after normalization to ß-actin and MAP2 (Table 2 and
Fig. 3B).
4. Discussion
This study is the ﬁrst to demonstrate the localization of ˛1-
chimaerin mRNA in the brains of human AD patients and control
subjects, and to compare the expression levels of ˛1-chimaerin
mRNA between temporal cortex samples from both groups. In situ
hybridization histochemistry demonstrated ˛1-chimaerin mRNA
in the temporal cortex neurons of both control subjects and AD
cases, with the AD brains showing a reduced signal intensity of
˛1-chimaerin mRNA compared to controls. The neuronal local-
ization of ˛1-chimaerin is consistent with previous reports using
rats [2,7,8]. In the rat brain, ˛1-chimaerin mRNA is expressed
speciﬁcally in neurons and expression rapidly increases post-
natally [8], although interestingly, expression was high in the
cortex, including the entorhinal cortex and hippocampus, and
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the amygdala [8]. These regions are known to be vulnerable in
AD.
In agreement with the in situ hybridization results, the real-
time PCR analysis conﬁrmed a signiﬁcantly reduced expression
level of ˛1-chimaerin mRNA in the temporal cortex of AD brains
compared to controls. When the expression level was normalized
to that of MAP2 mRNA, ˛1-chimaerin mRNA expression was sig-
niﬁcantly reduced in the AD brains. These results suggest that the
reduction of ˛1-chimaerin is not due simply to neuronal loss, but
that it could reﬂect a pathological mechanism.
When normalized to ß-actin and MAP2, the expression of ˛2-
chimaerin mRNA showed no signiﬁcant difference between the AD
cases and control subjects. These results are in good agreement
with a previous study using the rat brain [8], and suggest that ˛1-
chimaerin is the main form of this GAP protein in the adult brain.
The precise roles of ˛1-chimaerin in the pathology of AD are
not revealed in this study. However, there are several possibilities.
Synapse development and plasticity are controlled by Rho GTPase
regulatory proteins [23], and chimaerins are one class of Rho GAPs
with a GAP domain speciﬁc for Rac. GAPs are generally thought to
downregulate the activity of small GTPases such as Rac1, as active
GTP-bound forms become inactive GDP-bound forms. Therefore,
a reduction in ˛1-chimaerin would be expected to increase Rac1
activity at that location. This is in agreement with a previous paper
showing that Rac1 activitywas increased in the brain of ADpatients
[19]. In addition, increased expression of Rac1b, a constitutively
active splice variant of Rac1, increased only within neurons in AD
[24]. Taking together, these ﬁndings suggest that the alterations in
˛1-chimaerin and Rac1 in AD brains could be one of the mecha-
nisms underlying synaptic dysfunction.
The other possibility is that ˛1-chimaerin is associated in some
way with cyclin-dependent kinase 5 (Cdk5). Cdk5 is a neuron-
speciﬁc Rac effector [25], and ˛1-chimaerin exists in a functional
complexwith Cdk5 in the brain [26]. Cdk5 is thought to be involved
in the phosphorylation and aggregation of tau protein, tangle for-
mation, and Aß neurotoxicity in the brain of AD patients [27,28].
Thus, it will be of great interest to clarify the interaction between
˛1-chimaerin and Cdk5.
5. Conclusion
In this study, we investigated the expression and localization
of ˛1-chimaerin mRNA in postmortem brains from patients with
ADand control subjects. In situ hybridization studies demonstrated
that ˛1-chimaerin was expressed by neurons in the temporal lobe
and the hippocampus, and staining intensity was reduced in AD
cases. Real-time PCR analysis conﬁrmed a signiﬁcant reduction
of ˛1-chimaerin mRNA expression in the brain of AD cases com-
pared to controls, while there was no signiﬁcant difference in
˛2-chimaerin mRNA levels between the groups.
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